Geometry.Net - the online learning center
Home  - Health_Conditions - Fatty Oxidation Disorders
e99.com Bookstore
  
Images 
Newsgroups
Page 4     61-80 of 93    Back | 1  | 2  | 3  | 4  | 5  | Next 20
A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

         Fatty Oxidation Disorders:     more detail
  1. Fatty Acid Oxidation: Clinical, Biochemical, and Molecular Aspects (Progress in Clinical and Biological Research) by Kay Tanaka, 1990-07

61. The American Journal Of The Medical Sciences - UserLogin
Genetic disorders in fatty acid oxidation are reviewed in the last three articles.Drs. Barger and Kelly describe an essential role for transcriptional
http://www.amjmedsci.com/pt/re/ajms/fulltext.00000441-199907000-00001.htm
LWWOnline LOGIN eALERTS REGISTER ... Archive You are attempting to access protected content.
To access this content please login using an established account or create/activate an account.
If you have already created/ activated an online account, please login below: User Name: Password: Note: passwords are CASE SENSITIVE
If you are a new user or guest visiting an LWWonline site for the first time, please complete the new account setup process to view or purchase content.

Subscribe to RSS feed utrdc-pt02
Release 4.0

62. Arrhythmias And Conduction Defects As Presenting Symptoms Of Fatty Acid Oxidatio
fatty Acid oxidation disorders and Arrhythmias in 24 Patients The prevalenceof fatty acid oxidation disorders in the different reported series of
http://circ.ahajournals.org/cgi/content/full/100/22/2248
This Article Abstract Full Text (PDF) Alert me when this article is cited ... Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal ... Request Permissions PubMed PubMed Citation Articles by Bonnet, D. Articles by Saudubray, J.-M. Related Collections Arrhythmias, clinical electrophysiology, drugs
Oxidant stress

Pediatric and congenital heart disease, including cardiovascular surgery
Circulation.
Clinical Investigation and Reports
Arrhythmias and Conduction Defects as Presenting Symptoms of Fatty Acid Oxidation Disorders in Children
Damien Bonnet, MD Delphine Martin, MD Pascale de Lonlay, MD Elizabeth Villain, MD Philippe Jouvet, MD Daniel Rabier, MD Jean-Marie Saudubray, MD
Abstract Top
Abstract
Introduction
Methods
Results
Discussion
References
Background of fatty acid oxidation vary according to the enzymatic defect. They may present as isolated cardiomyopathy, sudden death, progressive skeletal myopathy, or hepatic failure. Arrhythmia is an unusual presenting

63. Arrhythmias And Conduction Defects As Presenting Symptoms Of Fatty Acid Oxidatio
Background—The clinical manifestations of inherited disorders of fatty Arrhythmia is an unusual presenting symptom of fatty acid oxidation deficiencies.
http://circ.ahajournals.org/cgi/content/abstract/100/22/2248
This Article Full Text Full Text (PDF) Alert me when this article is cited ... Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal ... Request Permissions PubMed PubMed Citation Articles by Bonnet, D. Articles by Saudubray, J.-M. Related Collections Arrhythmias, clinical electrophysiology, drugs
Oxidant stress

Pediatric and congenital heart disease, including cardiovascular surgery
Circulation.
Clinical Investigation and Reports
Arrhythmias and Conduction Defects as Presenting Symptoms of Fatty Acid Oxidation Disorders in Children
Damien Bonnet, MD Delphine Martin, MD Pascale de Lonlay, MD Elizabeth Villain, MD Philippe Jouvet, MD Daniel Rabier, MD Jean-Marie Saudubray, MD Background of fatty acid oxidation vary according to the enzymatic defect. They may present as isolated cardiomyopathy, sudden death, progressive skeletal myopathy, or hepatic failure. Arrhythmia is an unusual presenting symptom of fatty acid oxidation deficiencies.

64. Fetal Fatty Acid Oxidation Disorders, Their Effect On Maternal Health And Neonat
Mitochondrial fatty acid oxidation disorders (FAOD) are recessively inheritederrors of metabolism. Newborns with FAOD typically present with hypoketotic
http://www.pedresearch.org/cgi/content/abstract/57/5_Part_2/78/R
HOME HELP FEEDBACK SUBSCRIPTIONS ... TABLE OF CONTENTS QUICK SEARCH: [advanced] Author:
Keyword(s):
Year: Vol: Page:
Published online before print April 6, 2005
This Article Full Text Full Text (PDF) All Versions of this Article:
01.PDR.0000159631.63843.3Ev1

57/5_Part_2/78/R most recent correspondence: Submit a response Alert me when this article is cited Alert me when correspondence are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager PubMed PubMed Citation Articles by SHEKHAWAT, P. S. Articles by STRAUSS, A. W. Pediatric Research
International Pediatric Research Foundation, Inc.

DOI: 10.1203/01.PDR.0000159631.63843.3E
Fetal Fatty Acid Oxidation Disorders, Their Effect on Maternal Health and Neonatal Outcome: Impact of Expanded Newborn Screening on Their Diagnosis and Management
PREM S. SHEKHAWAT DIETRICH MATERN and ARNOLD W. STRAUSS

65. Pediatric Research -- Sign In Page
THE MITOCHONDRIAL fatty ACID ßoxidation disorders More than 20 defects in fatty Rinaldo P, Matern D, Bennett MJ 2002 fatty acid oxidation disorders.
http://www.pedresearch.org/cgi/content/full/57/5_Part_2/78/R
HOME HELP FEEDBACK SUBSCRIPTIONS ... SEARCH QUICK SEARCH: [advanced] Author:
Keyword(s):
Year: Vol: Page:
This item requires a subscription to Pediatric Research Online.
Full Text
Fetal Fatty Acid Oxidation Disorders, Their Effect on Maternal Health and Neonatal...
SHEKHAWAT et al. Pediatr Res.
This Article Abstract Full Text (PDF) correspondence: Submit a response ... Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager PubMed PubMed Citation Articles by SHEKHAWAT, P. S. Articles by STRAUSS, A. W. To view this item, select one of the options below: Sign In User Name Sign in without cookies.
Can't get past this page?

Help with Cookies.

Need to Activate?
Password Forgot your user name or password? Purchase Short-Term Access Pay per Article - You may access this article (from the computer you are currently using) for 1 day for US$20.00 Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

66. Newborn Bloodspot Screening
Problems in getting energy from fats are called fatty Acid oxidation disorders.The 9 fatty acid oxidation disorders included in the Maryland Newborn
http://www.fha.state.md.us/genetics/html/nbs_bloodspot.html
Center for Cancer Surveillance and Control Council on Physical Fitness Genetics and Children Center for Maternal and Child Health Center for Preventive Health Services Child and Adolescent Health Health Promotion, Education Oral Health Deer's Head Center Western Maryland Center GENETICS HOME Newborn Screening Genetic Counseling Infant Hearing Screening ... Contact Us
Newborn Bloodspot Screening Program
All babies born in Maryland, over 70,000 annually, are eligible for this service. We also accept specimens on babies born out of state to Maryland residents. There is a one time $42.00 laboratory charge per baby. This is billed to the hospital of birth. No baby is ever refused testing for inability to pay. The hospital is not charged for testing if the family is unable to pay. What is a disorder of body chemistry?

67. Newborn Bloodspot Disorders Screening
(Some well known organic acidurias and fatty acid oxidation disorders are listed The fatty acid oxidation disorders included in the Maryland Newborn
http://www.fha.state.md.us/genetics/html/newborn.html
Center for Cancer Surveillance and Control Council on Physical Fitness Genetics and Children Center for Maternal and Child Health Center for Preventive Health Services Child and Adolescent Health Health Promotion, Education Oral Health Deer's Head Center Western Maryland Center GENETICS HOME Newborn Screening Genetic Counseling Infant Hearing Screening ... Contact Us
Newborn Bloodspot Disorders
Disorders Included in the Newborn Bloodspot Screening Program
The Maryland Newborn Screening Program finds babies with any of 32 disorders:
Biotinidase Deficiency * Homocystinuria PKU CAH ... Organic Acidurias (13) Note: Babies are also screened for Hearing Loss (Some well known organic acidurias and fatty acid oxidation disorders are listed separately as well as under the group heading.) Biotinidase Deficiency The body is unable to recycle the B vitamin called biotin. Biotin is needed to make a number of enzymes. Babies with this deficiency need more biotin than other babies. Treatment with extra biotin prevents the mental retardation and deafness, which would otherwise result. This disorder can be considered an organic aciduria. Approximately 1 in 60,000 U.S. babies has this problem.

68. In Vivo Stable Isotope Studies In Three Patients Affected With Mitochondrial Fat
fatty acid oxidation disorders limited diagnostic use of 113C fatty acid The in vivo oxidation of fatty acids (FA) of different chain length was
http://www.pdg.cnb.uam.es/UniPub/iHOP/gp/1162448.html
In vivo stable isotope studies in three patients affected with mitochondrial fatty acid oxidation disorders: limited diagnostic use of 1-13C fatty acid breath test using bolus technique.The in vivo oxidation of fatty acids (FA) of different chain length was investigated in three patients with documented mitochondrial FA oxidation disorders: one patient with mild multiple acyl-CoA dehydrogenase deficiency ( MADM ), one with medium chain acyl-CoA dehydrogenase deficiency ( MCAD ), and one with carnitine palmitoyltransferase I deficiency ( CPT I
Breath tests were performed after oral administration of 1-13C butyric.
1-13C octanoic, and 1-13C palmitic acids.
13C/12C ratio in the expired oxidative end product CO2 was measured.
The cumulative 13C elimination was calculated and expressed as a percentage of the administered dose.
In the MADM patient the influence of carnitine therapy (or deprivation) on the utilization of 1-13C palmitic acid was also examined.
In the MCAD and CPT I patients, the 1-13C butyric, 1-13C octanoic and 1-13C palmitic acids in vivo oxidation were similar to five healthy controls.

69. Legislative Information System
Adds to the list of inherited disorders for which newborn testing is required a fatty acid oxidation disorder known as MCAD or MCADH, ie, mediumchain
http://leg1.state.va.us/cgi-bin/legp504.exe?021 sum SB218S

70. Treatment Of Cardiomyopathy And Rhabdomyolysis In Long-chain Fat Oxidation Disor
Mitochondrial fatty acid oxidation disorders. In The metabolic and molecularbases of inherited disease. 8th edition. CR Scriver, AL Beaudet, WS Sly,
http://www.jci.org/cgi/content/full/110/2/259
QUICK SEARCH: [advanced] Author:
Keyword(s):
Year: Vol: Page:
This Article Abstract Full Text (PDF) Submit a response ... Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal ... Cited by other online articles PubMed PubMed Citation Articles by Roe, C. R. Articles by Brunengraber, H. J Clin Invest, July 2002, Volume 110, Number 2, 259-269
Article
Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride
Charles R. Roe Lawrence Sweetman Diane S. Roe France David and Henri Brunengraber Institute of Metabolic Disease, Baylor University Medical Center, Dallas, Texas, USA
Department of Nutrition, Case Western Reserve University, Cleveland, Ohio, USA Address correspondence to: Charles R. Roe, Institute of Metabolic Disease, Baylor University Medical Center, 3812 Elm Street, Dallas, Texas 75226, USA. Phone: (214) 820-4533; Fax: (214) 820-4853; E-mail: Received for publication February 20, 2002

71. Treatment Of Cardiomyopathy And Rhabdomyolysis In Long-chain Fat Oxidation Disor
fat oxidation disorders using an anaplerotic oddchain triglyceride The current dietary treatment of long-chain fatty acid oxidation defects (high
http://www.jci.org/cgi/content/abstract/110/2/259
QUICK SEARCH: [advanced] Author:
Keyword(s):
Year: Vol: Page:
This Article Full Text Full Text (PDF) Submit a response ... Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal ... Cited by other online articles PubMed PubMed Citation Articles by Roe, C. R. Articles by Brunengraber, H. J Clin Invest, July 2002, Volume 110, Number 2, 259-269
Article
Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride
Charles R. Roe Lawrence Sweetman Diane S. Roe France David and Henri Brunengraber Institute of Metabolic Disease, Baylor University Medical Center, Dallas, Texas, USA
Department of Nutrition, Case Western Reserve University, Cleveland, Ohio, USA Address correspondence to: Charles R. Roe, Institute of Metabolic Disease, Baylor University Medical Center, 3812 Elm Street, Dallas, Texas 75226, USA. Phone: (214) 820-4533; Fax: (214) 820-4853; E-mail: Received for publication February 20, 2002

72. Todd Richmond's Thesis - Defects Of Beta-oxidation In Humans
The consequences of being unable to degrade fatty acids are severe. human diseases attributed to peroxisomal and mitochondrial betaoxidation disorders.
http://cellwall.stanford.edu/thesis/thesis09.htm
Defects of beta-oxidation in humans
The consequences of being unable to degrade fatty acids are severe. There are a number of human diseases attributed to peroxisomal and mitochondrial beta-oxidation disorders. Peroxisomal disorders can be classified into two broad categories: assembly disorders, affecting the biogenesis of peroxisomes, and single enzyme defects (Moser and Moser, 1996). Zellweger cerebro-hepato-renal syndrome, neonatal adrenoleukodystrophy (ALD) and infantile phytanic acid storage disease are examples of diseases characterized by a decreased number or absence of peroxisomes in liver and other tissues (Watkins et al., 1989; Brown et al., 1993). The clinical features of these disorders include dimorphic features, retinopathy, hypotonia, seizures, neuronal migration defects, liver disease and demyelination. Multiple biochemical abnormalities are observed as well, including the accumulation of very long chain fatty acids (VLCFA) (Moser et al., 1984).
There are at least 10 disorders caused by the loss of a single peroxisomal enzyme (Moser and Moser, 1996). Deficiencies in beta-oxidation enzymes include X-linked adrenoleukodystrophy, and deficiencies of acyl-CoA oxidase, bifunctional enzyme, and peroxisomal thiolase. X-linked adrenoleukodystrophy is caused by the loss of a single bifunctional protein acting in the beta-oxidation pathway. This deficiency causes disease symptoms similar to Zellweger syndrome or neonatal ALD, both assembly disorders (Watkins et al., 1989). Peroxisomal bifunctional enzyme deficiency results in multiple biochemical abnormalities including elevated levels of very long chain fatty acid levels in both plasma and fibroblasts, impaired beta-oxidation in cultured fibroblasts, and abnormal bile acid metabolism (Watkins et al., 1989).

73. Fat Oxidation Defect Presenting With Overwhelming Ketonuria -- Wraige Et Al. 87
Inherited disorders of fatty acid oxidation classically present with The commonest metabolic disorder by far is the fatty acid oxidation defect medium
http://adc.bmjjournals.com/cgi/content/full/87/5/428

HOME
HELP FEEDBACK SUBSCRIPTIONS ... TABLE OF CONTENTS Author
Keyword(s)
Vol Page [Advanced] This Article Abstract Full Text (PDF) Submit a response ... Alert me if a correction is posted Services Email this link to a friend Similar articles in ADC Online Similar articles in PubMed Alert me to new issues of the journal ... Download to citation manager PubMed PubMed Citation Articles by Wraige, E Articles by Robinson, P H Related Collections Other Neurology
Nutrition and Metabolism

Children
Archives of Disease in Childhood
Archives of Disease in Childhood
CASE REPORT
Fat oxidation defect presenting with overwhelming ketonuria
E Wraige M P Champion C Turner and R N Dalton
Correspondence to:
Accepted for publication 12 April 2002
ABSTRACT
Ketonuria accompanying hypoglycaemia is conventionally thought to exclude fat oxidation defects. We describe a 2 year old girl with hypoglycaemic encephalopathy in whom a diagnosis of very long chain acyl CoA dehydrogenase deficiency was suggested on the basis of acylcarnitine analysis despite massive ketonuria.

74. Analysis Of Fatty Acid Oxidation Intermediates In Cultured Fibroblasts To Detect
method for the diagnosis of mitochondrial fatty acid oxidation disorders that The diagnosis and likely site of a mitochondrial fatty acid oxidation
http://www.clinchem.org/cgi/content/abstract/40/12/2267
HOME HELP FEEDBACK SUBSCRIPTIONS ... TABLE OF CONTENTS QUICK SEARCH: [advanced] Author:
Keyword(s):
Year: Vol: Page:
Clinical Chemistry

This Article Full Text (PDF) Submit a response Alert me when this article is cited ... Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal ... Cited by other online articles PubMed PubMed Citation Articles by Pourfarzam, M. Articles by Bartlett, K.
Analysis of fatty acid oxidation intermediates in cultured fibroblasts to detect mitochondrial oxidation disorders
M Pourfarzam, J Schaefer, DM Turnbull and K Bartlett
Department of Child Health, Medical School, University of Newcastle upon Tyne, UK. We describe a method for the diagnosis of mitochondrial fatty acid oxidation disorders that is based on the analysis of acylcarnitine and acyl-coenzyme A (acyl-CoA) esters generated during fatty acid oxidation by permeabilized skin fibroblasts. This method requires only small amounts of cultured fibroblasts with minimal preparation, and no isolation of

75. Identification And Quantification Of Intermediates Of Unsaturated Fatty Acid Met
acid metabolism in plasma of patients with fatty acid oxidation disorders acids and their 3hydroxy analogs in fatty acid ß-oxidation disorders
http://www.clinchem.org/cgi/content/abstract/41/10/1467
HOME HELP FEEDBACK SUBSCRIPTIONS ... TABLE OF CONTENTS QUICK SEARCH: [advanced] Author:
Keyword(s):
Year: Vol: Page:
Clinical Chemistry

This Article Full Text (PDF) Submit a response Alert me when this article is cited ... Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal ... Cited by other online articles PubMed PubMed Citation Articles by Onkenhout, W. Articles by Poorthuis, B. J.
Identification and quantification of intermediates of unsaturated fatty acid metabolism in plasma of patients with fatty acid oxidation disorders
W Onkenhout, V Venizelos, PF van der Poel, MP van den Heuvel and BJ Poorthuis
Department of Pediatrics, University Hospital, Leiden, The Netherlands. The free fatty acid and total fatty acid profiles in plasma of nine patients with medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, two with very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency and two with mild-type multiple acyl-CoA dehydrogenase (MAD-m) deficiency, were analyzed

76. Human Placenta Metabolizes Fatty Acids: Implications For Fetal Fatty Acid Oxidat
Mitochondrial fatty acid oxidation disorders in an affected fetus are associatedwith maternal diseases of pregnancy, including preeclampsia, acute fatty
http://ajpendo.physiology.org/cgi/content/short/00481.2002v1
HOME HELP FEEDBACK SUBSCRIPTIONS ... SEARCH QUICK SEARCH: [advanced] Author:
Keyword(s):
Year: Vol: Page:
Am J Physiol Endocrinol Metab (February 11, 2003). doi:10.1152/ajpendo.00481.2002
This Article Full Text (PDF) All Versions of this Article:
most recent
Alert me when this article is cited
Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal ... Cited by other online articles PubMed PubMed Citation Articles by Shekhawat, P. S. Articles by Strauss, A. W. Submitted on November 5, 2002
Accepted on February 6, 2003
Human Placenta Metabolizes Fatty Acids: Implications for Fetal Fatty Acid Oxidation Disorders and Maternal Liver Diseases
Prem S. Shekhawat Michael J. Bennett Yoel Sadovsky D. Michael Nelson Dinesh Rakheja and Arnold W. Strauss Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA
Departments of Pathology and Pediatrics, University of Texas-Southwestern Medical Center, Dallas, TX, USA
Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO, USA

77. The Newborn Screening Disorders
The newborn screen tests for these seven fatty acid oxidation disorders A baby with a fatty acid oxidation disorder must have regular medical care.
http://www.dhfs.state.wi.us/DPH_BFCH/Newborn_Screen/NBSdisorders.htm
Topics A-Z Reference Center Search Family Health Home ... Staff Contacts
The Newborn Screening Disorders
This page will describe the disorders tested for by the newborn screen. If you have additional questions about these disorders, please ask your health care provider or go to additional information Biotinidase
Deficiency
Congenital Adrenal Hyperplasia (CAH) ... Fatty Acid Oxidation Disorders
Biotinidase Deficiency
Back to top
Congenital Adrenal Hyperplasia ( CAH)
Back to top
Congenital Hypothyroidism
Back to top
Cystic Fibrosis (CF)
Cystic fibrosis causes thick mucus to collect in the lungs and intestines. Mucus prevents proper breathing and can cause poor digestion of food. Lung infections and digestive problems will need medical treatment. A baby with CF will need regular medical care and a good diet. Back to top
Galactosemia
A baby with this problem cannot digest the sugar galactose. If not treated, galactose will build up in the body causing damage to the eyes, liver and brain. Babies with galactosemia must not have foods containing galactose or lactose, including breast milk and some infant formulas. Treatment includes a special diet and regular medical care.

78. ODS Director - Paul M. Coates
Roe CR, Coates PM Mitochondrial fatty acid oxidation disorders. In The Metabolicand Molecular Bases of Inherited Disease (Scriver CR, Beaudet AL, Sly WS,
http://dietary-supplements.info.nih.gov/About/ODS_Director.aspx
Paul M. Coates, Ph.D., Director, ODS
Paul M. Coates, Ph.D. was appointed Director of the Office of Dietary Supplements (ODS) at the NIH effective October 25, 1999. He served from 1996-1999 as Deputy Director of the Division of Nutrition Research Coordination (DNRC) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). In that role, Dr. Coates helped to coordinate human nutrition research efforts, both at the NIH and between the NIH and other government agencies. Among these efforts was Healthy People 2010 , the initiative from the U.S. Department of Health and Human Services (DHHS) to set public health goals for the nation. Dr. Coates co-leads the development of the Nutrition/Overweight chapter for which he received the NIH Director's Award for outstanding activities. Dr. Coates acted as Co-Chair of the joint DHHS/USDA Steering Committee overseeing plans for the National Nutrition Summit that was held in Washington in May 2000. He also is a member of the Federal Steering Committee that oversees the development of the Dietary Reference Intakes. Prior to joining the DNRC, Dr. Coates was NIDDK's Program Director for the Type 2 Diabetes Research Program (1993-1996) and Project Officer for the multi-center clinical study called Epidemiology of Diabetes Interventions and Complications (1994-1996). From 1994 until his departure from NIDDK, he maintained an active interest in career development and fellowship training in the Division of Diabetes, Endocrinology, and Metabolic Diseases.

79. Peroxisomal Fatty Acid Oxidation Disorders And 58 KDa Sterol Carrier Protein X (
Peroxisomal fatty acid oxidation disorders and 58 kDa sterol carrier protein X A new peroxisomal ßoxidation disorder in twin neonates defective
http://www.jlr.org/cgi/content/full/41/3/336
HOME HELP FEEDBACK SUBSCRIPTIONS ... TABLE OF CONTENTS QUICK SEARCH: [advanced] Author:
Keyword(s):
Year: Vol: Page:
This Article Abstract Full Text (PDF) Purchase Article ... Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager ... Cited by other online articles PubMed PubMed Citation Articles by Ferdinandusse, S. Articles by Wanders, R. J. A. Journal of Lipid Research, Vol. 41, 336-342, March 2000
Lipid Research, Inc.
Original Article
Peroxisomal fatty acid oxidation disorders and 58 kDa sterol carrier protein X (SCPx): activity measurements in liver and fibroblasts using a newly developed method
Sacha Ferdinandusse a , Simone Denis a , Emanuel van Berkel a , Georges Dacremont b , and Ronald J. A. Wanders a
a Departments of Clinical Chemistry and Pediatrics, Academic Medical Center, University of Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands
b Department of Pediatrics, University of Ghent, Ghent, Belgium Correspondence to: Ronald J. A. Wanders

80. Peroxisomal Fatty Acid Oxidation Disorders And 58 KDa Sterol Carrier Protein X (
Peroxisomal fatty acid oxidation disorders and 58 kDa sterol carrier proteinX (SCPx) activity measurements in liver and fibroblasts using a newly
http://www.jlr.org/cgi/content/abstract/41/3/336
HOME HELP FEEDBACK SUBSCRIPTIONS ... TABLE OF CONTENTS QUICK SEARCH: [advanced] Author:
Keyword(s):
Year: Vol: Page:
This Article Full Text Full Text (PDF) Purchase Article ... Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager ... Cited by other online articles PubMed PubMed Citation Articles by Ferdinandusse, S. Articles by Wanders, R. J. A. Journal of Lipid Research, Vol. 41, 336-342, March 2000
Lipid Research, Inc.
Original Article
Peroxisomal fatty acid oxidation disorders and 58 kDa sterol carrier protein X (SCPx): activity measurements in liver and fibroblasts using a newly developed method
Sacha Ferdinandusse a , Simone Denis a , Emanuel van Berkel a , Georges Dacremont b , and Ronald J. A. Wanders a
a Departments of Clinical Chemistry and Pediatrics, Academic Medical Center, University of Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands
b Department of Pediatrics, University of Ghent, Ghent, Belgium Correspondence to: Ronald J. A. Wanders

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

Page 4     61-80 of 93    Back | 1  | 2  | 3  | 4  | 5  | Next 20

free hit counter